Clinical trials
Moderate to Severe Atopic Dermatitis clinical trials
Below are recruiting moderate to severe atopic dermatitis clinical trials, each written for real people, not researchers. We’re tracking 95 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07444801Recruiting
Tralokinumab for eczema with genital symptoms
This trial tests if tralokinumab, a drug already approved for moderate-to-severe eczema, helps people who also have eczema in the genital area. It aims to understand how well the drug works for this specific symptom.
Augsburg, MünchenAges 18 years+ - NCT07445919RecruitingPhase 2
Testing SM17 for moderate-to-severe eczema
This trial tests an investigational drug called SM17 for people with moderate-to-severe atopic dermatitis (eczema). It aims to see if SM17 can reduce itching and skin symptoms when topical treatments haven't worked well enough.
BeijingAges 18–70 - NCT07441395RecruitingPhase 2
Study of soquelitinib for moderate to severe eczema
This trial tests an experimental pill called soquelitinib for people with moderate to severe eczema (atopic dermatitis). It aims to see if the drug can reduce symptoms like itching and skin inflammation.
South San Francisco, CaliforniaAges 18 years+ - NCT06815380Recruiting
Study on lebrikizumab for people with atopic dermatitis
This study looks at how lebrikizumab (Ebglyss) affects daily life and skin symptoms in adults with moderate-to-severe eczema. You may join if your doctor has prescribed this medication as part of your regular care.
Aarhus, DenmarkAges 18 years+ - NCT07399067RecruitingPhase 2
Testing IBI3002 for moderate to severe eczema
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
Beijing, Beijing MunicipalityAges 18–75 - NCT07370909RecruitingPhase 3
Oral LW402 for moderate-to-severe eczema
This trial tests an oral pill called LW402 for people with moderate-to-severe atopic dermatitis (eczema). It aims to see if the drug is safe and effective at reducing skin symptoms.
BeijingAges 18–75 - NCT07355075RecruitingPhase 2/Phase 3
Study of a new cream for moderate to severe eczema
This study tests an investigational cream for moderate to severe eczema. It helps see if the cream reduces symptoms like itching and skin inflammation.
Irving, TexasAges 18–80 - NCT06850311RecruitingPhase 2/Phase 3
Herbal ointment for mild to severe eczema
This trial tests whether a special herbal ointment can help treat atopic dermatitis (eczema). It is for adults with mild, moderate, or severe eczema covering less than 10% of their body surface. The ointment is applied directly to the skin, and participants will also use a gentle, fragrance-free moisturizer.
New Taipei CityAges 18–65 - NCT07330934RecruitingPhase 2
Study of IBI356 for moderate to severe eczema
This study tests a new medication called IBI356 for people with moderate to severe eczema that hasn't improved with standard creams. The goal is to see if this medicine can safely reduce the redness, itching, and rash.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07309055RecruitingPhase 3
Study of SHR-1819 injection for teens with severe eczema
This trial tests an injectable medicine called SHR-1819 for teenagers aged 12 to 17 with severe atopic dermatitis (eczema) that has not responded well to creams or other treatments. The goal is to see if it can improve skin symptoms and reduce itching.
Shenyang, LiaoningAges 12–17 - NCT07298395RecruitingPhase 2
Study of ENV-294 for moderate-to-severe eczema
This trial tests an experimental cream or pill called ENV-294 in adults whose eczema is moderate to severe and hasn't gotten better with standard creams. It aims to see if ENV-294 can help control symptoms like itching and skin redness.
Birmingham, AlabamaAges 18–75 - NCT07297602RecruitingPhase 2
Oral roflumilast for moderate to severe eczema in teens and adults
This study tests an oral medicine called roflumilast to see if it helps treat moderate to severe eczema in people aged 12 and up who haven't used other systemic treatments recently. It's a pilot study to check both safety and how well it works.
Al Mansurah, Dakahlia GovernorateAges 12 years+ - NCT06882148Recruiting
How long do eczema patients stay on targeted therapies?
This study looks at how long people with moderate to severe eczema stay on newer targeted medicines (biologics or pills). By reviewing medical records, researchers hope to learn which treatments work best over time and how they are used in real life.
RomeAges 18 years+ - NCT07239947RecruitingPhase 1
Testing BBT001 for healthy volunteers and people with eczema
This trial tests a new medicine called BBT001, first in healthy people and then in adults with moderate to severe eczema (atopic dermatitis). It aims to see if the drug is safe and how well it works for treating eczema that hasn't improved with topical treatments.
Hefei, AnhuiAges 18–65 - NCT07235384RecruitingPhase 1
Zai Lab tests ZL-1503 for moderate to severe eczema
This study tests a new medication called ZL-1503 for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The trial will check if the drug is safe and how well it works.
Woolloongabba, QueenslandAges 18–65 - NCT07211542RecruitingPhase 2
Study of SHR-1905 for moderate-to-severe eczema
This trial tests a new drug called SHR-1905 for people with moderate-to-severe atopic dermatitis (a type of eczema). It aims to see if the drug is safe and helps improve symptoms.
Guangzhou, GuangdongAges 18–75 - NCT07204561Recruiting
CeraVe cream for keeping skin hydrated after atopic dermatitis treatment
This trial tests whether using CeraVe moisturizer can keep your skin hydrated and prevent flare-ups after your eczema has been cleared with a steroid treatment. It is for adults with mild to moderate eczema that gets better with steroids.
Roma, RMAges 18–99 - NCT07193589RecruitingPhase 2
Testing ZL-82 tablets for moderate to severe eczema
This study tests if an oral tablet called ZL-82 can help people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to other treatments. It aims to find a new option for controlling this chronic skin condition.
Chengdu, SichuanAges 18–75 - NCT07180511Enrolling by invitationPhase 3
A study of QY201 tablets for moderate to severe eczema
This trial tests a new pill called QY201 for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. It aims to see if QY201 can help control itching and skin inflammation.
Hangzhou, ZhejiangAges 18–75 - NCT05819463Recruiting
Study care for moderate to severe atopic dermatitis
This trial looks at treatment and medical care for teens and adults with moderate to severe atopic dermatitis (eczema). It may help by testing ways to manage symptoms better based on severity and current treatment needs.
BaselAges 12 years+ - NCT06587685RecruitingPhase 3
PG-011 gel for eczema in teens and adults
This trial tests a new gel called PG-011 for people with mild to moderate eczema (atopic dermatitis). The gel is applied to the skin, and the study will check if it helps improve symptoms safely.
Shenyang, LiaoningAges 12–75 - NCT07042126RecruitingPhase 3
Testing 611 for Teen Eczema (moderate to severe)
This trial tests a new injectable medicine (611) for teenagers with moderate to severe eczema that hasn't been helped enough by creams. It aims to see if the drug can safely reduce itching and skin symptoms.
Beijing, Beijing MunicipalityAges 12–17 - NCT07037901RecruitingPhase 2
Testing IMG-007 for moderate-to-severe eczema
This study tests a new medicine called IMG-007 for adults with moderate-to-severe eczema (atopic dermatitis) that hasn't gotten better with standard creams. The goal is to see if it safely reduces itching and skin symptoms.
Lancaster, CaliforniaAges 18–74 - NCT06988605Recruiting
Nemolizumab for teens and adults with moderate-to-severe eczema
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
Birmingham, AlabamaAges 12 years+
Hear when a new Moderate to Severe Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for moderate to severe atopic dermatitis?
- Yes. Clin2 currently lists 95 recruiting moderate to severe atopic dermatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a moderate to severe atopic dermatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a moderate to severe atopic dermatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.